Objective:

To evaluate the safety and effectiveness of bevacizumab combined with the FOLFOX regimen for the treatment of colorectal cancer.

Key Findings:

• Bevacizumab plus FOLFOX significantly improved overall response rate (ORR) and disease control rate (DCR) compared to FOLFOX alone.
• No significant differences in gastrointestinal reactions, leukopenia, liver injury, neurotoxicity, or hypertension were observed overall.
• Substantial heterogeneity was noted for hypertension, addressed using a random-effects model.
• Sensitivity analyses indicated robustness of main efficacy findings.

Interpretation:

Bevacizumab combined with FOLFOX may enhance short-term efficacy outcomes in advanced or metastatic colorectal cancer patients.

Limitations:

• Insufficient evidence for long-term survival benefit and quality-of-life improvement.
• Heterogeneity in hypertension results may affect generalizability.

Conclusion:

While the combination may improve short-term outcomes, further research is needed to assess long-term effects.